Literature DB >> 11221873

Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen.

T D Schell1, J D Lippolis, S S Tevethia.   

Abstract

Recent reports have documented the presence of SV40 large T antigen (T ag) sequences in a number of human tumors and raised the question of whether cellular immunity to T ag is elicited in such individuals. We used HLA-A2.1 transgenic C57BL/6 mice to identify an epitope from T ag recognized by CD8+ CTLs when presented by this human MHC class I molecule. Immunization of HLA-A2.1 transgenic mice with syngeneic T ag-transformed cells resulted in the induction of HLA-A2.1-restricted, T ag-specific CTLs. The target epitope, residues 281-289 (KCDDVLLLL) of T ag, was identified using both cell lines expressing T ag variants and synthetic T ag peptides. Peptide 281-289 bound stably to HLA-A2.1 molecules, effectively sensitized target cells for CTL lysis, and was efficiently processed from endogenous T ag in cells of both mouse and human origin. CTLs were not cross-reactive on the human BK or JC virus T ags. Thus, SV40 T ag 281-289 represents a potential specific CTL recognition epitope for humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11221873

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Nancy Cladel; Karla Balogh; Neil Christensen
Journal:  Vaccine       Date:  2010-03-21       Impact factor: 3.641

2.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

3.  Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines.

Authors:  Jiafen Hu; Todd D Schell; Xuwen Peng; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Vaccines Vaccin       Date:  2010-08-20

4.  Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model.

Authors:  Jiafen Hu; Xuwen Peng; Lynn R Budgeon; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

5.  An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants.

Authors:  Hephzibah Rani S Tagaram; Alan M Watson; Francois A Lemonnier; Kevin Staveley-O'Carroll; Satvir S Tevethia; Todd D Schell
Journal:  Virology       Date:  2008-04-10       Impact factor: 3.616

6.  Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.

Authors:  Alan M Watson; Lawrence M Mylin; Megan M Thompson; Todd D Schell
Journal:  J Immunol       Date:  2012-11-21       Impact factor: 5.422

7.  Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein.

Authors:  Michael D Street; Tracy Doan; Karen A Herd; Robert W Tindle
Journal:  Immunology       Date:  2002-08       Impact factor: 7.397

8.  Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors.

Authors:  Maurizio Provenzano; Laura Bracci; Stephen Wyler; Tvrtko Hudolin; Giovanni Sais; Rainer Gosert; Paul Zajac; Giorgio Palu'; Michael Heberer; Hans H Hirsch; Giulio C Spagnoli
Journal:  J Transl Med       Date:  2006-11-10       Impact factor: 5.531

9.  A safety-modified SV40 Tag developed for human cancer immunotherapy.

Authors:  Stephanie S Tseng-Rogenski; Mohamed S Arredouani; June F Escara-Wilke; Yilin C Neeley; Michael J Imperiale; Martin G Sanda
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein.

Authors:  Baomei Wang; Huabiao Chen; Xiaodong Jiang; Minghui Zhang; Tao Wan; Nan Li; Xiangyang Zhou; Yanfeng Wu; Feng Yang; Yizhi Yu; Xiaoning Wang; Ruifu Yang; Xuetao Cao
Journal:  Blood       Date:  2004-03-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.